BeOne Medicines Ltd. Form 8-K Summary
Business Context and Reporting Period
BeOne Medicines Ltd. filed this Current Report on Form 8-K on April 14, 2026, to disclose the filing of its 2025 Annual Report with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. The report covers the fiscal year ended December 31, 2025. The company is incorporated in Switzerland and lists American Depositary Shares on the NASDAQ Global Select Market under the symbol ONC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice that financial information prepared under China Accounting Standards (PRC GAAP) is available in the STAR Annual Report. Additional financial data prepared under U.S. GAAP, including gross profit margin ratios and R&D expenses, is referenced as being contained in Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing does not detail specific material changes in financial performance versus the prior period. It notes that PRC GAAP differs from U.S. GAAP and that a summary of material differences between the two accounting standards is included in Exhibit 99.1.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, or specific risk factors. It explicitly states that the STAR Annual Report and the Shanghai Stock Exchange website are not part of this Form 8-K filing and are not deemed filed with the U.S. SEC. The information furnished in Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act.
Investor Verification Checklist
- Verify the full 2025 Annual Report on the Shanghai Stock Exchange website (www.sse.com.cn) for detailed PRC GAAP financials.
- Review Exhibit 99.1 (not included in this text) for U.S. GAAP reconciliations, gross profit margins, and R&D expense allocations.
- Confirm the specific material differences between PRC GAAP and U.S. GAAP as outlined in the referenced exhibit.
- Note that the primary financial disclosure is in Chinese and not formally filed with the U.S. SEC.